All In Biotech

Drug Trial Radar · NCT05876767

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

A Randomized, Double-blind, Placebo-controlled Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Subcutaneous Doses of SAR444336 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Oct 15, 2021

Primary completion

Dec 12, 2023

Study completion Dec 12, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 study will assess the safety and tolerability, and characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of SAR444336 in healthy subjects following single- and repeated-dose administrations as a first step in clinical development prior to administering this new investigational medicinal product (IMP) to patients.

Conditions

  • Healthy Volunteer

Interventions

  • SAR444336Drug

    Single or repeated dose subcutaneous injection

  • PlaceboDrug

    Single or repeated dose subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: Until Day 43
  2. Part 2: Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: Until Day 85

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number :5280001

    Leiden, Leiden, Netherlands

  • Investigational Site Number :5280002

    Groningen, Provincie Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.